Latest Ratios: P/E Ratio -58.8x · EV/EBITDA N/A · ROE -46.9%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $706M | $1.1B | $1.4B | $93M | $4M | $2278 | $1M | $2M | $6M | — | — |
| Enterprise Value | $706M | $1.1B | $1.5B | $94M | $12M | $-258496 | $1M | $3M | $6M | — | — |
| P/E Ratio → | -58.83 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 16.63 | 26.57 | 69.50 | 15.84 | 2.76 | — | — | — | — | — | — |
| P/B Ratio | 18.35 | 29.53 | 106.64 | 6.51 | — | 0.02 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 26.56 | 70.36 | 16.04 | 8.28 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.0% | 46.0% | 40.9% | 12.1% | 33.6% | — | — | — | — | — | — |
| Operating Margin | -19.3% | -19.3% | -91.9% | -351.5% | -389.4% | — | — | — | — | — | — |
| Net Profit Margin | -28.5% | -28.5% | -92.7% | -356.2% | -384.1% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -46.9% | -46.9% | -138.0% | -360.5% | — | -1050.3% | — | — | — | -1026.5% | — |
| ROA | -20.8% | -20.8% | -56.4% | -129.0% | -151.2% | -397.7% | -499.4% | -2436.3% | -293.1% | -258.7% | -166.0% |
| ROIC | -17.8% | -17.8% | -61.0% | -148.7% | -162.2% | — | — | — | — | — | — |
| ROCE | -23.7% | -23.7% | -101.8% | -268.0% | — | -995.6% | — | — | — | -999.9% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 1.35 | 0.57 | — | 1.03 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | 1.32 | 0.08 | — | -1.85 | — | — | — | -4.48 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -6.36 | -6.36 | -18.68 | -39.01 | -33.58 | — | -1061.02 | — | — | -37.43 | -20.54 |
Net cash position: cash ($3M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | 1.86 | 1.29 | 1.98 | 0.53 | 1.42 | 0.14 | 0.03 | 0.09 | 1.13 | 0.38 |
| Quick Ratio | 1.21 | 1.21 | 0.81 | 1.30 | 0.41 | 1.42 | 0.14 | 0.03 | 0.09 | 1.13 | 0.38 |
| Cash Ratio | 0.12 | 0.12 | 0.02 | 0.76 | 0.03 | 1.41 | 0.14 | 0.02 | 0.08 | 1.11 | 0.38 |
| Asset Turnover | — | 0.57 | 0.49 | 0.23 | 0.21 | — | — | — | — | — | — |
| Inventory Turnover | 1.34 | 1.34 | 1.19 | 0.82 | 1.07 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 106.52 | 126.52 | 102.26 | 623.85 | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $199M | $182M | $128M | $4M | $3M | $2M | $2M | $2M | $2M | $2M |
Insufficient liquidity for scale
Based on reported figures, SSII trades at a P/S multiple of 15.73, which appears to price in aggressive future growth expectations that significantly outpace the company's current ability to generate positive earnings, as evidenced by the TTM P/E ratio of -55.67 and lack of positive free cash flow.
The current valuation multiple suggests that investors are assigning a high premium to the company's potential market disruption rather than its current financial performance. This pricing is particularly aggressive when compared to the broader medical device sector, implying that any delay in regulatory milestones or commercial adoption could lead to a significant downward re-rating of the stock.
According to quarterly financial data, SSII has consistently reported negative ROIC, with figures reaching -6.9% in 2026Q1, indicating that the company is currently destroying shareholder value rather than compounding it as it attempts to scale its robotic surgical platform in highly competitive emerging markets.
The persistent negative returns on invested capital reflect the heavy burden of R&D and infrastructure costs that have yet to be offset by sufficient gross profit margins. Without a clear path to positive operating margins, the company's ability to generate sustainable returns on capital remains highly speculative and dependent on future scale.
As reported in financial statements, the company's cash conversion cycle remains highly volatile, peaking at 393 days in 2024Q4, which suggests significant friction in managing inventory and accounts receivable compared to the more streamlined operational cycles observed in established medical device peers like Intuitive Surgical.
The extended duration of the cash conversion cycle indicates that capital is being tied up in inventory and uncollected receivables for prolonged periods. This inefficiency places additional strain on the company's already limited liquidity, as it must fund these working capital requirements while simultaneously managing high operating expenses.
Based on the most recent quarterly filings, the company's liquidity position appears increasingly precarious, with a cash balance of $3.2M that provides a very limited runway to support ongoing operations and global expansion efforts in the face of persistent negative free cash flow margins.
The current ratio of 2.54 may provide a false sense of security, as a significant portion of current assets is likely tied up in inventory that may not be easily liquidated. Investors should monitor the company's ability to secure additional financing, as the current cash position appears insufficient to sustain the business through its next phase of growth.
The P/S ratio is frequently misapplied to SSII, as it fails to account for the high proportion of low-margin hardware sales versus the recurring revenue streams that characterize successful robotic surgery business models, thereby masking the company's underlying lack of profitability and high operational burn rate.
Relying on the P/S ratio ignores the critical distinction between transactional system placements and the high-margin consumable revenue that drives long-term value in this industry. A more appropriate metric would be the ratio of recurring revenue to total revenue, which would better reflect the company's progress toward a sustainable and scalable business model.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SSII stock.
SS Innovations International, Inc.'s current P/E ratio is -58.8x. This places it at the 50th percentile of its historical range.
SS Innovations International, Inc.'s return on equity (ROE) is -46.9%. The historical average is -181.8%.
Based on historical data, SS Innovations International, Inc. is trading at a P/E of -58.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
SS Innovations International, Inc. has 46.0% gross margin and -19.3% operating margin.